Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part...

Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators
as Part of Long-Term Commitment to Fight the Disease

Program helps diabetes educators better engage and motivate their patients
with the goal of more positive outcomes.

INDIANAPOLIS, June 30 /PRNewswire/ -- Roche, the maker of ACCU-CHEK blood
glucose monitoring systems and insulin pumps, announced today the latest
component of its Behavior Change through Patent Engagement (sm) program.
Creative Coaching is an advanced educational program that fights the growing
epidemic of diabetes by improving dialogue between diabetes educators and
their patients.

"As the world leader in diabetes diagnostics, we truly appreciate the efforts
of educators, and other healthcare professionals, who help their patients lead
healthier lifestyles," said Sr. Vice President & General Manager of Roche
Diabetes Care North America Luc Vierstraete. "They represent the front lines
in the fight against poorly managed diabetes and its devastating effects.
These professionals are already so adept at the science of diabetes - this
program helps them with the art of patient engagement."

Recent participants in the program say they value not only the foundation of
adult learning styles and coaching skills, but also the ability to interact
with one another while learning how to effectively integrate ACCU-CHEK
products and tools. When educators return to their practices they are better
prepared to apply best practices and achieve breakthroughs with their
patients.

"What I appreciated most was the purpose of the weekend, which was to increase
the quality of our healthcare," said Diabetes Educator Linda Filipi, BSN, RN
of Laguna Hills, California. "For us that means how to become better
educators - for (Roche) it is how to offer quality products. The end result
is the same: it means that patients live longer, healthier and happier lives."

Creative Coaching is just one part of the Behavior Change through Patient
Engagement program. Other elements include education to healthcare
professionals on psychological barriers to self-care, direct-to-patient
education that helps adults, children and teens make self-management easier;
and simple, paper-based tools that help patients discover how the actions they
take every day matter.

"A worldwide strategic objective for Roche is to 'Enable Diabetes
Management,'" Vierstraete said. "We take this very seriously - in the U.S.
alone we have invested more than $14 million in the overall campaign. By
locking arms with these dedicated healthcare professionals and providing them
with a forum to improve patient self-care, we feel certain this can be
achieved."

About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose
monitoring systems and a global leader for diabetes management systems and
services. For more than 30 years, Roche has been committed to helping people
with diabetes live lives that are as normal and active as possible and has
been helping healthcare professionals manage their patients' condition in an
optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and
healthcare professionals innovative products, services and comprehensive
solutions for convenient, efficient and effective diabetes management--from
blood glucose monitoring through information management to insulin delivery.
The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing
and data management systems.

For more information, please visit accu-chek.com.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche
is the world's largest biotech company with truly differentiated medicines in
oncology, virology, inflammation, metabolism and CNS. Roche is also the world
leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer
in diabetes management. Roche's personalized healthcare strategy aims at
providing medicines and diagnostic tools that enable tangible improvements in
the health, quality of life and survival of patients.

In 2008, Roche had over 80,000 employees worldwide and invested almost 9
billion Swiss francs in R & D. The Group posted sales of 45.6 billion Swiss
francs. Genentech, United States, is a wholly owned member of the Roche Group.
Roche has a majority stake in Chugai Pharmaceutical, Japan. For more
information: www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:
Julie Vincent
Public Relations Manager
ACCU-CHEK(R) Brand
julie.vincent@roche.com
317-521-1910

SOURCE Roche Diabetes Care

Julie Vincent, Public Relations Manager, ACCU-CHEK(R) Brand,
julie.vincent@roche.com, +1-317-521-1910